Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
暂无分享,去创建一个
M. Battaglia | F. Selvaggi | F. Boccardo | A. Rubagotti | F. Zattoni | A. Siragusa | A. Manganelli | G. Martorana | A. Bertaccini | G. Conti | F. Montefiore | G. Comeri | F. Durand | A. Macchiarella | D. Potenzoni | P. Galassi | P. Di Tonno | G. Muscas | V. Ferraris | P. D. Tonno | Francesco Boccardo | Michele Battaglia | Giario Conti | Giuseppe Martorana
[1] T. Tammela,et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. , 2002, The Journal of urology.
[2] M. Wirth,et al. The bicalutamide Early Prostate Cancer Program. Demography. , 2001, Urologic oncology.
[3] P. Iversen,et al. Gynecomastia in patients with prostate cancer: a review of treatment options. , 2000, Urology.
[4] T. Tammela,et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. , 2000, The Journal of urology.
[5] P. Ditonno,et al. Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] T. Tammela,et al. A Randomised Comparison of ‘Casodex’TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer , 1998, European Urology.
[7] T. Tammela,et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. , 1998, Urology.
[8] D. Lebwohl,et al. Tamoxifen adminstration is associated with a high rate of treatment‐limiting symptoms in male breast cancer patients , 1994 .
[9] F. Boccardo,et al. Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer. , 1993, Acta endocrinologica.
[10] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[11] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[12] Tyrrell Cj. Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators. , 1994 .
[13] M. Ziveri,et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group. , 1993, European journal of cancer.